When the immune system is attacked by bacteria-generated toxins, the patient may suffer from severe, harmful reactions. For example, tetanus is a serious bacterial infection that attacks the human nervous system and makes the muscles tightened. Other symptoms may include fever, sweating, and headache. In order to inactivate these toxins in the human and animal bodies, toxoid vaccines are used. A toxoid vaccine is basically made of formalin (solution of formaldehyde and sterilized water). It is adsorbed onto calcium and aluminum salts to improve the immune response. Toxoid vaccines are safe to use and less vulnerable to changes in the atmosphere. Currently, toxoid vaccines are manufactured by culturing the highly toxigenic strain of Clostridium tetani. It is followed by ultrafiltration. Components of toxoid vaccines include antigens, stabilizers, adjuvants, antibiotics, and preservatives. Most toxoid vaccines are administered through the parenteral (intramuscular) route.
The global toxoid vaccines market is driven by several factors such as rising prevalence of tetanus and diphtheria (Bibersteinia trehalosi infection, Corynebacterium pseudotuberculosis infection, enterotoxemia, pox, etc. in animals); increasing awareness about the severity of tetanus; high rate of diagnosis and treatment of tetanus and diphtheria and recommended number of doses of toxoid vaccines In the next few years, the toxoid vaccines market is likely to face challenges such as pain at the site of injection, side-effects, high prices of vaccines, weak supply chain network in developing countries, and stringent regulatory policies. On the other hand, new treatment options, government initiatives to implement vaccination programs in developing countries, investments in the development of toxoid vaccines, and technological breakthroughs are anticipated to open new avenues for growth of the market in the near future.
Based on vaccine type, the global toxoid vaccines market has been categorized into tetanus vaccines, diphtheria vaccines, pertussis vaccines, and others (botulism). Currently, toxoid vaccines are used in humans as well as animals to counter the bacterial toxins. Hence, in terms of application, the global toxoid vaccines market can be segmented into human vaccines and veterinary vaccines. The veterinary vaccines segment has been sub-classified into companion animals and livestock animals. Based on end-user, the global toxoid vaccines market has been categorized into hospitals, independent clinics, households, and others (including government camps and health centers).
Geographically, the global toxoid vaccines market has been classified into five regions such as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to the Centers for Disease Control & Prevention, the number of reported tetanus cases worldwide declined by more than 95% between 1974 and 2014 and the current incidence rate is around 0.1 per 1 million people per year. The European Center for Disease Prevention & Control reported 117 cases of tetanus in human population in Europe in 2017, of which Italy accounted for 41% of cases. The average notification rate was 0.3 cases per 1 million human population in Europe in 2015. In the Asia Pacific region, neonatal and maternal tetanus is considered one of the major health concerns by health care practitioners. In the Asia Pacific region, the number of deaths have been going down since last five years. According to a study published in the International Journal of Preventive Medicine in 2017, the number of neonatal tetanus cases declined significantly from 80,000 in 1980 to 500 in 2013. The same trend is also observed in China and countries in South Asia including Pakistan in 2016, owing to the rise in awareness about hygiene and increase in vaccinations. North America and Europe are estimated to hold a significant market share of the global toxoid vaccines market during the forecast period.
Prominent players that have commercialized toxoid vaccines for human application are MassBiologics, Sanofi Pasteur, GlaxoSmithKliene Biologics, Grifols, Panacea Biotec, Halfkin Bio-Pharmaceuticals Corporation Ltd., Bengal Chemicals & Pharmaceuticals Ltd., Serum Institute of India, Bharat Pharmaceuticals, and Henry Schein Medical. On the other hand, Colorado Serum Company, Zoetis, and Merck Sharp & Dohme Corp have commercialized toxoid vaccines for veterinary application across the world.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.